From Polydeoxyribonucleotides (PDRNs) to Polynucleotides (PNs): Bridging the Gap Between Scientific Definitions, Molecular Insights, and Clinical Applications of Multifunctional Biomolecules.
Level 5 - mechanism / opinion, no new human data
Narrative review proposing a nomenclature framework without primary clinical data or systematic review methodology
PubMed 39858543 · doi:10.3390/biom15010148
What was done
This narrative review examined the molecular weight ranges, physicochemical properties, and clinical aesthetic/dermatological applications (such as skin regeneration, inflammation reduction, and wound healing) of DNA-derived biopolymers to resolve interchangeable terminology between polydeoxyribonucleotides (PDRNs) and polynucleotides (PNs).
What was found
The abstract reports no quantitative clinical outcome numbers. It notes that biopolymer molecular weights historically ranged from 50 to 1500 kDa, recently expanding from 1 to 10,000 kDa. The authors propose the "Marques Polynucleotide Cutoff" at 1500 kDa, designating fragments <1500 kDa as PDRNs and fragments ≥1500 kDa as PNs based on differences in physicochemical properties and biological effects.
Why it matters
Inconsistent and interchangeable terminology between PDRN and PN products complicates scientific literature and clinical practice in aesthetic dermatology; a clear molecular weight threshold aims to standardize future research and product classification.
Limits
This is a narrative review presenting expert opinion and proposed nomenclature rather than new primary empirical human data or a systematic review. The abstract provides no numerical clinical efficacy data, and the proposed cutoff represents author-proposed nomenclature rather than an established international consensus standard.
Cited by
- supports Salmon sperm DNA isolates are used topically in facial rejuvenation treatments with aesthetic benefits.